Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX | BCRX Message Board Posts


BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  12745 of 12779  at  6/28/2021 2:20:23 PM  by

moegrabbedmythumb


Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX

 
Editing cells’ genomes with CRISPR-Cas9 might increase the risk that the altered cells, intended to treat disease, will trigger cancer, two studies published on Monday warn—a potential game-changer for the companies developing CRISPR-based therapies.

In the studies, published in Nature Medicine, scientists found that cells whose genomes are successfully edited by CRISPR-Cas9 have the potential to seed tumors inside a patient. That could make some CRISPR’d cells ticking time bombs, according to researchers from Sweden’s Karolinska Institute and, separately, Novartis. - June 12, 2018.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 [3]
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
12746 Re: Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX moshes 1 6/28/2021 2:31:47 PM
12747 Re: Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX mdaddy1234 1 6/28/2021 3:49:22 PM


Financial Market Data provided by
.
Loading...